BioStem Technologies (BSEM) Stock Chart & Stock Price History → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free BSEM Stock Alerts 7.66 -0.12 (-1.54%) (As of 06/5/2024 09:07 PM ET) Add Compare Share Share ChartStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest BioStem Technologies Stock Price Performance5 Day Performance-1.92%1 Month Performance-4.25%3 Month Performance-10.20%6 Month Performance+111.02%Year-To-Date Performance+30.72%1 Year Performance+283.00% Receive BSEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Brooks EnterprisesHow’d you do in 20222022 was a rough year. At their worst, the S&P 500 was down over 25% and the NASDAQ was down over 35%, and to make things even more interesting the Fed was seemingly raising interest rates every week!Get those kind of results during the Great Financial Crisis, without having to study more BSEM Stock Chart for Thursday, June, 6, 2024 BSEM Chart by TradingView BioStem Technologies Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/05/20247.787.66-1.54%7.877.5015,700 shs$124.78 million06/04/20247.857.78-0.89%7.877.7514,200 shs$126.74 million06/03/20247.817.85+0.51%7.967.623,000 shs$127.88 million05/31/20247.957.81-1.76%8.007.656,000 shs$127.23 million05/30/20248.417.95-5.47%8.507.9517,400 shs$129.51 million05/29/20247.618.41+10.51%8.987.6515,400 shs$137.00 million Get the Latest News and Ratings for BSEM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter. 05/28/20247.407.61+2.84%7.707.008,800 shs$123.97 million05/27/20247.407.407.737.1126,500 shs$120.52 million05/24/20247.457.40-0.67%7.737.1126,500 shs$120.55 million05/23/20247.957.45-6.29%7.957.2512,900 shs$121.34 million05/22/20247.757.95+2.65%7.957.757,700 shs$129.51 million05/21/20248.087.75-4.15%8.087.7111,800 shs$126.17 million05/20/20248.148.08-0.74%8.207.8523,000 shs$131.62 million05/17/20249.018.14-9.66%9.207.6544,000 shs$132.60 million05/16/20249.709.01-7.11%9.999.0120,300 shs$146.77 million05/15/20249.279.70+4.64%10.059.6143,800 shs$158.01 million05/14/20248.809.27+5.34%9.758.5733,300 shs$151.01 million05/13/20248.058.80+9.32%9.207.6125,600 shs$143.33 million05/10/20249.358.05-13.90%9.648.0133,900 shs$131.11 million05/09/20249.389.35-0.32%9.929.3522,900 shs$152.28 million05/08/20249.309.38+0.86%9.509.308,600 shs$152.77 million05/07/20248.569.30+8.70%9.728.5769,900 shs$151.50 million05/06/20248.008.56+6.95%8.687.9633,000 shs$139.37 million05/03/20248.998.00-11.01%9.007.9649,300 shs$130.30 million05/02/20249.248.99-2.71%9.298.5623,800 shs$146.45 million05/01/20249.019.24+2.55%9.248.9622,100 shs$149.97 million04/30/20249.309.01-3.12%9.359.0115,700 shs$146.23 million04/29/20249.119.30+2.14%9.399.1425,200 shs$150.94 million04/26/20249.409.11-3.14%9.559.1119,900 shs$147.77 million04/25/20249.369.40+0.48%9.609.4033,600 shs$152.56 million04/24/20249.249.36+1.24%9.409.0924,000 shs$151.80 million04/23/20249.559.24-3.25%9.509.0431,800 shs$149.97 million04/22/20249.709.55-1.55%9.799.3017,000 shs$155.00 million04/19/20249.809.70-1.02%9.769.2319,900 shs$157.40 million04/18/202410.009.80-2.00%10.059.5627,000 shs$159.05 million04/17/20249.4610.00+5.71%10.109.6538,700 shs$163.40 million04/16/202411.609.46-18.45%11.609.1977,461 shs$154.58 million04/15/202412.6511.60-8.30%12.8011.6033,700 shs$189.54 million04/12/202413.8512.65-8.66%13.9012.4532,500 shs$206.70 million04/11/202414.3913.85-3.75%14.4113.8338,200 shs$226.31 millionA once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.To get its name and ticker symbol for free - just click here.04/10/202414.4014.39-0.07%14.4514.3121,000 shs$235.13 million04/09/202414.3414.40+0.42%14.4914.104,700 shs$235.30 million04/08/202414.1014.34+1.70%14.5014.1036,200 shs$234.32 million04/05/202413.1514.10+7.22%14.1913.0038,600 shs$230.45 million04/04/202413.8913.15-5.33%13.9012.1921,800 shs$214.87 million04/03/202413.2313.89+4.99%14.1013.2323,500 shs$226.96 million04/02/202415.5013.23-14.65%15.5010.7656,200 shs$216.18 million04/01/202411.9815.50+29.38%15.5011.7571,000 shs$253.27 million03/29/202411.9811.9811.989.90111,300 shs$195.75 million03/28/20249.8511.98+21.62%11.989.90111,300 shs$195.75 million03/27/20249.589.85+2.82%9.969.6428,900 shs$160.95 million03/26/20249.509.58+0.84%9.799.4214,600 shs$156.54 million03/25/20249.399.50+1.17%9.959.3536,400 shs$155.23 million03/22/20249.639.39-2.49%9.639.385,500 shs$153.43 million03/21/20249.509.63+1.37%9.649.307,700 shs$157.35 million03/20/20249.459.50+0.53%9.649.3014,400 shs$155.27 million03/19/20249.609.45-1.56%9.609.3410,800 shs$154.41 million03/18/20249.629.60-0.21%9.609.3513,100 shs$156.86 million03/15/20249.509.62+1.26%9.649.3011,800 shs$157.23 million03/14/20249.399.50+1.17%9.709.4025,700 shs$155.04 million03/13/20249.459.39-0.63%9.659.3912,600 shs$153.25 million03/12/20249.639.45-1.87%9.649.304,200 shs$154.22 million03/11/20249.569.63+0.73%9.659.0015,700 shs$157.16 million03/08/20249.659.56-0.93%9.659.3511,400 shs$156.02 million03/07/20249.279.65+4.10%9.659.1542,200 shs$157.49 million03/06/20248.539.27+8.68%9.398.7511,600 shs$151.31 million03/05/20249.378.53-8.96%9.608.5115,000 shs$139.21 million03/04/20249.079.37+3.31%9.869.0548,900 shs$152.92 million Related Companies: KalVista Pharmaceuticals Stock Chart Pacific Biosciences of California Stock Chart Fulcrum Therapeutics Stock Chart Avid Bioservices Stock Chart COMPASS Pathways Stock Chart OmniAb Stock Chart Astria Therapeutics Stock Chart IGM Biosciences Stock Chart Mesa Laboratories Stock Chart Corbus Pharmaceuticals Stock Chart Receive BSEM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:BSEM) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioStem Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioStem Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
